Introduction
With an estimated incidence of 2 cases per million people per year, osteosarcoma is the most frequent primary bone malignant tumor excluding hematopoietic intraosseous tumors. Osteosarcoma generally affects young patients with a peak incidence at 18 years old. The unifying histologic feature found in all types and subtypes of osteosarcomas is the presence of osteoid tissue produced by the neoplasic cells . As these tumors frequently penetrate and destroy the cortical substance of the bone and extend into the surrounding tissues, a
The final effector molecules that ultimately control osteolysis associated with tumor development in bone site are Receptor Activator of NF-kB Ligand (RANKL) and osteoprotegerin (OPG) . RANKL directly stimulates osteoclastic differenciation and osteoclast [3] activation and survival by signalling through its membrane receptor RANK, expressed on the osteoclast precursor surface. Physiologically, RANKL signalling is negatively regulated by the soluble antagonist receptor protein OPG which induces osteoclast apoptosis. Targeting RANKL signalling with OPG inhibits tumor associated osteolysis in several experimental bone tumor models including mouse colon adenocarcinoma, myeloma, breast, lung, prostate cancer and osteosarcoma . However, OPG has been shown to bind the TNF receptor [4] [5] [6] [7] [8] [9] TRAIL (TNF Related Apoptosis Inducing Ligand), and to block TRAIL-mediated apoptosis in cancer cells . Thus, alternative [10] [11] [12] [13] agents such as soluble RANK-Fc that block RANKL mediated bone resorption but that do not interact with TRAIL, may provide useful therapies to prevent tumor development in bone. RANK-Fc is a chimeric protein formed by fusing the four cysteine-rich pseudorepeats of RANK that are responsible for RANK-L binding with the Fc portion of human immunoglobulin G1 (IgG1). Moreover, RANK-Fc has the potential advantage over OPG of greater specificity for RANKL. Fusion of the four Cystein Rich Domains (CRD) of RANK to the constant region of hIgG1 dictates homodimerization which probably increases its avidity for RANKL. The sRANK differs from OPG because in addition to containing four CRDs, OPG also contains two death domains and a heparin binding domain . Accordingly, [14] RANK-Fc has been recently shown to cause a marked reduction in tumor burden in two SCID-hu-multiple myeloma models , and also [15] an inhibition of prostate cancer progression in bone . However, no study was performed on RANK-Fc effects in primary bone tumors. [16] Previous data showed that it is feasible to provide long-lasting expression of RANK-Fc at bone-protective levels using a retroviral gene therapy approach . However, the toxicity associated with the use of viral vectors is extremely complex involving both the innate [17] and adaptative immune responses. Recently, a new class of synthetic vectors has been reported for gene transfer in various organs in vivo including skeletal and cardiac muscles , and in lungs . These new synthetic vectors result from the association of plasmid DNA [18 19 ] [20] with amphiphilic polymers consisting in blocks of poly(ethylene oxide) and of poly(propylene oxide). Intramuscular injections of these synthetic vectors lead to the synthesis of proteins for local benefit such as dystrophin or for systemic use such as erythropoietin . [21] The aim of this study was to determine the therapeutic relevance of RANK-Fc in a murine osteolytic osteosarcoma model by using a non-viral gene transfer approach.
Material & Methods

Cell lines
-The osteosarcoma cell line POS-1, derived from mouse spontaneous osteosarcoma , was cultured in RPMI 1640 medium (Bio [22] Whittaker, Verviers, Belgium) supplemented with 10 fetal bovine serum (FBS, Hyclone, Perbio, France) and 2 mmol/L L-glutamine. 
experimentations In vitro
Plasmid constructions
The pcDNA3.1-RANK-Fc construction (kindly provided by Dr Choi Y., Philadelphia, USA) contains a DNA sequence encoding the extracellular domain of murine RANK (0.7 kb) fused to the coding sequences of the constant portion of human IgG1 (0.5 kb)
. The [23] soluble RANK-Fc cDNA is inserted in the pcDNA3.1 plasmid between XbaI and XhoI under the control of the CMV promoter. For the in and studies, the empty pcDNA3.1 was used as a control. vivo in vitro
Cell transfection
To assess the cellular expression of RANK-Fc, 2 g of pcDNA3.1 and pcDNA3.1-RANK-Fc were transfected by nucleofection into 
Osteoclasts differentiation
The biological activity of the transgene was compared between pcDNA3.1-RANK-Fc-and pcDNA3. Amgen Inc, Thousand Oaks, USA). After five days of culture, multinucleated cells (> 3 nuclei) were counted after a May Gr nwald ü Giemsa staining.
Cell proliferation
Replicate subconfluent cell cultures of POS-1 cells in 96-well plates were treated for 24 to 72 hours with increasing concentrations of murine RANK-Fc (R&D systems, Abingdon, UK) (0, 25, 50 and 100 ng/ml). Cell viability was determined by the sodium 3′[ Cells treated with 1 M staurosporin 6 hours before harvesting were used as a positive control for caspase activity. 
TRAIL biological activity
Replicate subconfluent cell cultures of human osteosarcoma MG63 cells in 96-well plates were treated for 72 hours with increasing concentrations of human TRAIL (R&D systems) (0, 50 and 100 ng/ml) in the presence or absence of 100 ng/ml RANK-Fc. Cell viability was determined by the XTT cell proliferation reagent assay kit as described above. the periostum of the diaphysis was opened and resected along a length of 5 mm, underlying bone was intact. The osteosarcoma fragment was placed contiguous to the exposed bone surface without periostum, and the cutaneous and muscular wounds were sutured. Tumors appeared at the graft site approximately 8 days later associated with the development of pulmonary metastases in a 3 week-period. The tumor that develops in contact to the tibia induces osteolytic lesions that reproduce the osteolytic form of human osteosarcoma . The [22] tumor volume (V) was calculated from the measurement of two perpendicular diameters using a calliper, according to the following formula: V 0.5 L (S) , where L and S are respectively the largest and smallest perpendicular tumor diameters. A model of pulmonary
metastases was developed to study RANK-Fc effect independent of bone environment, where mice were anaesthetized by inhalation of a mixture of isoflurane/air combined with an intramuscular injection of buprenorphine as described above prior to i.v. injection of 50 l of μ POS-1 cell suspension containing 1.5 10 cells. In these conditions, pulmonary metastases developed rapidly, leading to the death of the
animals in three weeks after POS-1 cell injection.
: for intramuscular injections, mice were anaesthetized with a combination isoflurane/air. Fifty microliters of Formulation preparations block copolymers/DNA formulations were injected into shaved tibial anterior muscles at one site using a microfine syringe (U100, Becton : to determine the effect of RANK-Fc delivered by synthetic vectors on osteosarcoma development, the mice Experimental protocols were transplanted with POS-1 osteosarcoma fragments as described above. Groups of 8 mice were assigned respectively as controls (no injection), control vectors (Lutrol /pcDNA3.1 alone) and RANK-Fc (Lutrol /pcDNA3.1-RANK-Fc). Preliminary results from the ® ® laboratory have already shown that the vector Lutrol alone does not affect tumor development in the same mouse osteosarcoma model ® [9] . A preventive treatment was applied, where the Lutrol /DNA formulations were injected into both tibial anterior muscles once a week, ® beginning 7 days before osteosarcoma implantation up to 21 days post-implantation. The tumor volume was calculated as described above.
Treatment continued until each animal showed signs of morbidity, which included cachexia or respiratory distress, at which point they were sacrificed by cervical dislocation. Lung tumor dissemination was assessed at necropsy.
Radiographs on animals anaesthetized with 50 mg/kg Nesdonal (Merial, Lyon, France) were taken every week and at the time of necropsy with a mammography PLANMED Sophie apparatus (SN RAH 40710, Helsinki, Finland). Analysis of architectural parameters was performed using the high resolution X-ray micro-CT system for small animal imaging SkyScan-1072 (SkyScan, Aartselaar, Belgium).
Relative volume (BV/TV) of the tibia total bone (cortical trabecular) or trabecular bone was quantified at necropsy in the osteosarcoma [ + ] groups that received RANK-Fc compared to that of control mice. The results of one representative experiment out of 3 are shown.
Gene and protein expression analysis
To assess RANK-Fc transgene expression at the mRNA and protein levels, pcDNA3.1-and in vitro pcDNA3.1-RANK-Fc-nucleofected RAW 264.7 cells were cultured in 6-well plates (2 10 per well) under standard conditions during 48
hours.
, blood was drawn intermittently from the retro-orbital vein to monitor serum RANK-Fc level (day 7, 10 or 15 post-injection). In vivo At necropsy, the tumor and muscle tissues were lysed in Reporter Lysis Buffer 1X (Promega, Madison, USA) supplemented with protease inhibitor cocktail (Roche Molecular Biomedicals, Manheim, Germany), broyed during 30 sec using Ultraturax , centrifuged at 10 000 rpm ® during 5 min at 4 C and were processed for RANK-Fc detection using the ELISA test described below.°R
NA extraction and semi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis
RANK-Fc mRNA expression was determined by RT-PCR after total RNA extraction using Trizol reagent (Invitrogen). First, RNA was reversed-transcribed (RT) using 400 U MMLV-RT from Invitrogen, then two microliters of the RT reaction mixture were subjected to PCR using upstream thanks to VICTOR Multilabel counter (Perkin ELMER, Waltham, USA). The ELISA detection limit was 0.02 ng/ml. 
Histology
After sacrifice, tibia were conserved and fixed in 10 neutral buffered formalin at 4 C, and embedded in Glycol Methyl Methacrylate
%°(
GMA) for TRAP staining, and 5-m sections were cut. The sections were stained for TRAP to identify osteoclasts by one hour incubation μ in a 2 mg/ml napthyl phosphate (Sigma Chemical Co) and 5 mg/ml Fast violet salt (Sigma Chemical Co) solution. The counterstain was performed with toluidine blue after a one hour inactivation of the first solution in sodium fluorure. The number of osteoclasts was evaluated on the cortical bone by manually counting by light microscopy.
Data analyses
For experimentations, the Tukey/Bonferroni test was used for microscanner and non parametrical test by Kruskal-Wallis in vivo analysis for the tumoral progression evaluation. The differences of actuarial survival were determined by the log-rank test on a Kaplan In vitro analysis of transgene expression mRANK-Fc overexpression was investigated at the mRNA and protein levels by RT-PCR and ELISA analyses performed on RAW 264.7 cells which were transfected with pcDNA3.1 or pcDNA3.1-RANK-Fc using the AMAXA nucleofector system. RT-PCR analysis showed a major expression of RANK-Fc mRNA in pcDNA3.1-RANK-Fc transfected cells whereas no expression was observed in the corresponding pcDNA3.1 transfected cells ( ). This result was confirmed at the protein level by ELISA analysis, as supernatant from Fig. 1a pcDNA3.1-RANK-Fc transfected cells showed a high level of murine RANK-Fc protein (101.6 15.88 ng/ml) after 48 hours, when ± compared to pcDNA3.1 transfected cells which showed no protein expression ( ). Fig. 1b 
In vivo validation of transgene expression
After injection of the DNA-Lutrol complexes into the tibial anterior muscles, an overexpression of the RANK-Fc transgene was ® measured both at systemic (serum) and local (muscle) levels in mice treated with pcDNA3.1-RANK-Fc. The production varied from 0.053 to 0.499 ng/ml in the serum and from 0.09 to 22.57 ng/ml in the muscle, being significantly higher to the pcDNA3.1 or control groups where no RANK-Fc expression could be detected, either in serum or in muscle ( ). No correlation could be established between Fig. 1c RANK-Fc concentration (either systemic or local) and its therapeutic efficacy. The immunogenicity of the human Fc part of RANK-Fc was checked previously in a immunocompetent rat model of osteosarcoma, and no antibodies were detected up to 3 weeks (not shown).
In vitro validation of transgene biological activity
To confirm that RANK-Fc expressed by non viral gene transfer was biologically active, we investigated its ability to block RANKL These results demonstrate that RANK-Fc protein is expressed after non viral gene transfer both and and that it exerts in vitro in vivo, an anti-resorption activity (against RANKL) and not a pro-tumoral one (unable to block TRAIL induced apoptosis) in vivo
Protective effect of mRANK-Fc transgene expression on bone resorption associated to osteosarcoma development
The mouse osteosarcoma POS-1 model used in this study has been previously associated with osteolytic lesions by micro-CT analysis . To demonstrate the inhibitory effect of RANK-Fc on the development of osteolytic lesions, mice transplanted with osteosarcoma [22] were treated with pcDNA3.1-RANK-Fc or pcDNA3.1 alone (control vector) using the amphiphile block copolymer Lutrol which had ® previously demonstrated the best transfection efficiency , . Because control tumors and pcDNA3.1 (control vector) treated in vivo [20 21] mice exhibit similar bone alterations , only pcDNA3.1 treated mice tibiae radiographs and micro-CT analyses were shown. Important [9] osteolytic lesions were observed on the tibia of POS-1 osteosarcoma bearing mice treated with pcDNA3.1 alone as compared to the pcDNA3.1-RANK-Fc group that exhibit minor lesions ( ). These results were confirmed by the bone microarchitecture analysis, as 
mRANK-Fc transgene expression limits osteosarcoma progression and increases animal survival
Mice received a preventive treatment with DNA-Lutrol complexes, the first injections being realized 7 days before osteosarcoma ® implantation. This strategy was chosen because in vivo transgene production is optimal 7 days after the construct injection, this timepoint corresponding to the day of tumor transplantation. The tumor volume was calculated twice a week following the measure of the two perpendicular diameters. The results show that the tumor volume of each animal was smaller in the RANK-Fc treated group compared to the pcDNA3.1 or the control groups ( ). As a result, the mean tumor volume 21 days after tumor implantation was significantly lower Fig 3a in the group receiving RANK-Fc compared to the pcDNA3.1 group or the control group (p<0.05), reaching respectively 1652.7 1055 mm 2000 mm ) is significantly lower at day 21 in the RANK-Fc treated animals (2/6) as compared to controls or pcDNA3.1 treated mice (6/6 3 for both, ). These results enabled us to calculate the relative tumor progression between day 12 and 21 which was significantly Fig. 3a  decreased by 62.7 (p<0.05) and 64.3 (p<0.01) in the RANK-Fc treated group as compared respectively to the pcDNA3.1 and untreated % % group ( ). As a consequence, a significant increase (p<0.02) of animal survival was observed with 57.1 of survival at day 28 in the All these results show that RANK-Fc not only exerts a protective effect on osteosarcoma associated bone lesions but also diminishes the tumor progression in bone, increasing the animal survival in an osteolytic model of osteosarcoma.
Expression of mRANK-Fc inhibits osteosarcoma progression by preventing bone resorption
Complementary to radiographic and micro-CT analyses, TRAP staining was performed on osteosarcoma sections from mice treated or These data demonstrate that the inhibitory effects observed on tumor progression for the RANK-Fc treated group are not due to in vivo a direct effect on POS-1 tumor cells.
RANK-Fc treatment does not affect tumor nodule development in lungs
As RANK-Fc exerts no direct effect on tumor cells, we hypothesize that the inhibitory effect observed in osteosarcoma development is the indirect consequence of bone resorption inhibition, thus depending on bone microenvironment. To demonstrate this hypothesis, another set of experiments was performed in mice developing tumor lesions in lungs. This model was induced after POS-1 cell injection in the retro-orbital vein. The results presented in show no significant differences between the different groups in the overall mouse Figure 6 survival rate, indicating that RANK-Fc exerts no inhibitory effect on tumor development outside the bone micro-environment.
Discussion
The mouse model of osteosarcoma used in this study is characterized by the presence of osteolytic lesions . The release of latent [24] growth factors (such as insulin growth factor, TGF-, BMP, PDGF and VEGF) stored in the bone matrix during osteolysis stimulates the gene transfer demonstrated the relevance of using such anti-resorptive factors as promising therapeutic approaches for primitive osteolytic tumors. However, the ability of OPG to block the TRAIL apoptosis pathway in cancer cells was noticed and there were concerns that this could lead to a burst in tumor growth . Denosumab is a fully human mAb directed against RANKL and is currently under investigation [30] in phase III clinical trials , . Denosumab was generated by immunizing the XenoMouse with full-length human RANKL protein, [31 32 ] [33] producing a fully human IgG1 mAb which recognizes an epitope with a single amino acid difference between the mouse and the human sequences. Because human IgG1 can induce complement-dependent cytotoxicity or antibody-dependent cell cytotoxicity to target cells [34] , it was converted to a noncytotoxic IgG2 mAb, known as Denosumab which has an extremely high affinity (Kd approximately 10 M) 12 − for human RANKL. The fact that Denosumab does not recognize rodent RANKL has complicated preclinical development, with only one relevant animal study conducted in cynomolgus monkeys . Therefore, as these anti-RANKL antibodies cannot be used in our mouse 7 12 model of osteosarcoma, RANK-Fc, another member of the TNF receptor family was used in the present study. Indeed, RANK-Fc, the fusion of the extracellular domain of RANK (amino acids 22-209) with the constant region of human immunoglobulin G1 (IgG1) has the potential advantage over OPG of greater specificity for RANKL . Delivery of RANK-Fc as a recombinant protein has shown [15] promising results as a potential therapy through experiments in animal models, in that RANK-Fc limits hypercalcemia and osteolysis induced by myeloma or prostate cancer and reduces bone tumor establishment in these models , , , . Moreover, a recent study [15 16 29 36] reported that RANK-Fc inhibition of RANKL has an anti-osteoclast activity at doses that have no detectable immunoregulatory activity [ . Even if long-lasting expression of RANK-Fc could be provided at bone-protective levels using a retrovirus-mediated gene transfer 37] approach by the use of genetically modified mesenchymal stem cells , the toxicity associated with the use of such viral vectors is [17] extremely complex.
The results from the present study validate the non viral gene transfer method and the therapeutic interest of RANK-Fc in osteosarcoma. This methodology has previously proved its efficacy to deliver and express therapeutic gene in the same mouse model of osteosarcoma . In the present study, we demonstrate that when injected every week, the DNA-Lutrol complexes can induce RANK-Fc
over-expression both at local (muscle) and systemic levels in sufficient quantities to induce anti-bone resorption activity. The overproduction reached its maximum 7 days after injection and lasted for 15 days at the systemic level. The intra-muscular injection of the RANK-Fc/Lutrol complexes induces a local RANK-Fc transgene production that blocks bone resorption, as confirmed by radiography, ® histology, and quantified by micro-CT analysis in an osteolytic model of osteosarcoma. Moreover, the same inhibitory effect on bone osteolytic lesions has been obtained by adenoviral delivery of RANK-Fc in a rat osteocondensant osteosarcoma (data already published; ,
.
27]
Given its role in osteoclastogenesis, it is likely that inhibition of osteosarcoma progression by RANK-Fc reflects, at least in part, its ability to inhibit bone resorption. Indeed, RANK-Fc has no direct activity on osteosarcoma cells, as demonstrated by studies on in vitro proliferation, migration, apoptosis, cell cycle or phenotype analysis. Furthermore, the observation that RANK-Fc did not diminish development of non osseous tumors (pulmonary tumor lesions induced by the same osteosarcoma POS-1 cells injected i.v.) suggests that the ability of RANK-Fc to inhibit osteosarcoma development was not caused by a direct effect on tumor but rather specific to factors in the bone microenvironment. Given that RANKL expression has been shown previously in the POS-1 tumor by immunohistochemical analyses , the present data suggest that inhibition of RANKL activity diminishes the osteosarcoma progression. Moreover, other experiments [9] performed in our laboratory have shown that osteosarcoma cells express RANK, and that RANKL is able to induce modulation of gene expression in these cells , , . Targeting RANKL is therefore a promising approach in bone tumor therapy. It has been demonstrated [24 38 39] that RANKL is implicated in the pathogenesis of bone metastasis at several levels: increased bone resorption as a result of excess RANKL results in the release of growth factors that facilitate tumor cell division and survival, and a recent study suggested a role for RANKL as a chemoattractant for certain cancer cells metastatic to bone . Furthermore, RANKL can stimulate both angiogenesis and endothelial [40] [41]
cell survival , suggesting a role for RANKL in supporting vascularization of bone metastases. This role could also be extended to [42] osteosarcoma, which is a naturally highly vascularized tumor. As RANKL participates to the regulation of Treg function, it could also interfere in tumor response at this level , .
To inhibit RANKL activity, three candidates are potentially promising: the decoy receptor OPG, the soluble receptor RANK-Fc constructed as the fusion of RANK extracellular domain with the constant region of the human IgG1, and antibodies directed against human RANKL. The advantage of using anti-RANKL antibodies is that they do not inhibit the TRAIL apoptosis pathway. In a recent randomized, double-blind, double dummy, active-controlled multicenter phase I clinical study, Body demonstrated the efficacy of et al [45] denosumab, A single subcutaneous dose of denosumab given to patients with multiple myeloma or bone metastasis from breast cancer yielded a dose dependent and sustained reduction in bone resorption. However, as this therapeutic agent cannot be used in immuno-competent models of bone tumors in rodents, RANK-Fc which is more specific of RANKL binding than OPG seems therefore a better therapeutic tool for these pathologies.
In conclusion, these data demonstrate that RANK-Fc delivered by non viral gene transfer is a promising therapeutic approach for osteolytic bone tumors such as osteosarcoma by targeting RANKL in the bone microenvironment.
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